The ratings of seven biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
SIGA Technologies, Inc.’s (SIGA) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. SIGA Technologies is a bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents such as smallpox and arenaviruses. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity and Cash Flow, SIGA also gets an F. The stock price has dropped 8.3% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at SIGA, get Portfolio Grader’s complete analysis of SIGA stock.
This week, Trius Therapeutics, Inc. (TSRX) drops from a C to a D rating. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
Nanosphere, Inc. (NSPH) experiences a ratings drop this week, going from last week’s C to a D. Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at NSPH, get Portfolio Grader’s complete analysis of NSPH stock.
Slipping from a C to a D rating, Sunesis Pharmaceuticals, Inc. (SNSS) takes a hit this week. Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. The stock also gets an F in Cash Flow. The stock price has been on the rise for the past two days, reaching $4.71. As of Feb. 10, 2014, 10% of outstanding Sunesis Pharmaceuticals, Inc. shares were held short. Trade volume is up 521% from the previous week. For more information, get Portfolio Grader’s complete analysis of SNSS stock.
Oncolytics Biotech’s (ONCY) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Oncolytics Biotech discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The stock gets F’s in Equity and Cash Flow. For a full analysis of ONCY stock, visit Portfolio Grader.
This is a rough week for Navidea Biopharmaceuticals, Inc. (NAVB). The company’s rating falls to F from the previous week’s D. Navidea Biopharmaceuticals is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. The stock gets F’s in Equity and Cash Flow. As of Feb. 10, 2014, 13.4% of outstanding Navidea Biopharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of NAVB stock.
Targacept, Inc. (TRGT) earns a D this week, moving down from last week’s grade of C. Targacept is an a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic acetylcholine receptors. The stock gets F’s in Equity, Cash Flow and Sales Growth. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. To get an in-depth look at TRGT, get Portfolio Grader’s complete analysis of TRGT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
